Roche's IMpassion130 Is First Positive Phase III Immunotherapy Study In Triple Negative Breast Cancer
Executive Summary
Phase III IMpassion130 study showed Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
You may also be interested in...
Pivotal Data Put Roche's Kadcyla In Position For Earlier Breast Cancer
KATHERINE supports filings for earlier use of Kadyla in adjuvant setting of breast cancer.
Key Cancer Data To Be Unveiled At ESMO In Munich
Big pharma and little biotechs are getting ready to pack their bags for Germany where over 2,000 abstracts will be presented at ESMO and the fine details on some major oncology studies will be closely watched.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.